[go: up one dir, main page]

MX2009002314A - Composiciones farmaceuticas que comprenden hgh para suministro oral. - Google Patents

Composiciones farmaceuticas que comprenden hgh para suministro oral.

Info

Publication number
MX2009002314A
MX2009002314A MX2009002314A MX2009002314A MX2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A
Authority
MX
Mexico
Prior art keywords
growth hormone
human growth
hgh
pharmaceutical compositions
oral delivery
Prior art date
Application number
MX2009002314A
Other languages
English (en)
Inventor
Moise Azria
Yatindra Joshi
Rosario Lobrutto
Linda Mindeholm
Ashish Bipin Patel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009002314A publication Critical patent/MX2009002314A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas de dosificación de la hormona de crecimiento humana, el uso de un aumentador de absorción para permitir la absorción de la hormona de crecimiento humana en la circulación sistémica en una forma biológicamente activa, en particular una administración oral, así como el uso de las formas de dosificación oral que comprenden la hormona de crecimiento humana y un aumentador de absorción para el tratamiento de las deficiencias de la hormona de crecimiento humana y desordenes saciados con la misma.
MX2009002314A 2006-08-31 2007-08-28 Composiciones farmaceuticas que comprenden hgh para suministro oral. MX2009002314A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82414006P 2006-08-31 2006-08-31
PCT/US2007/076932 WO2008027854A2 (en) 2006-08-31 2007-08-28 Pharmaceutical compositions comprising hgh for oral delivery

Publications (1)

Publication Number Publication Date
MX2009002314A true MX2009002314A (es) 2009-03-20

Family

ID=39000473

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002314A MX2009002314A (es) 2006-08-31 2007-08-28 Composiciones farmaceuticas que comprenden hgh para suministro oral.

Country Status (14)

Country Link
US (1) US8323688B2 (es)
EP (1) EP2059260B1 (es)
JP (1) JP5042312B2 (es)
KR (1) KR101524880B1 (es)
CN (2) CN103356997A (es)
AU (1) AU2007289344B2 (es)
BR (1) BRPI0716261A2 (es)
CA (1) CA2661521C (es)
ES (1) ES2426485T3 (es)
MX (1) MX2009002314A (es)
PL (1) PL2059260T3 (es)
PT (1) PT2059260E (es)
RU (1) RU2493868C2 (es)
WO (1) WO2008027854A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030271B2 (en) 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
WO2008112836A2 (en) * 2007-03-15 2008-09-18 Novartis Ag Pharmaceutical composition comprising human growth hormon
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
MX385591B (es) 2008-08-15 2025-03-18 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
US20120009225A1 (en) * 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
EP3278813A1 (en) * 2009-06-08 2018-02-07 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
MX2012001660A (es) 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
RU2605627C2 (ru) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Гормоны роста с пролонгированной эффективностью in vivo
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
CN103269720A (zh) 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
RS59978B1 (sr) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
EP2776055B1 (en) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
EP3416677B1 (en) 2016-02-17 2022-08-03 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
JOP20190019A1 (ar) 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
CR20230308A (es) * 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
HUP9900870A3 (en) * 1995-06-07 2001-04-28 Alkermes Inc Composition for sustained release of human growth hormone
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1093819B1 (en) 1997-02-07 2006-05-03 Emisphere Technologies, Inc. Compound and composition for delivering active agents
CA2294824A1 (en) * 1997-07-04 1999-01-14 Pharmacia & Upjohn Ab Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity
ATE288415T1 (de) 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
ATE443527T1 (de) * 2001-08-17 2009-10-15 Novartis Pharma Gmbh 5-cnac zur oralen verabreichung von parathormonfragmenten
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
CA2512052C (en) * 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
ES2380093T3 (es) * 2003-05-09 2012-05-08 Biogenerix Ag Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana
AU2004255458B2 (en) 2003-07-11 2007-09-13 Emisphere Technologies, Inc. Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
RU2368390C2 (ru) 2003-07-23 2009-09-27 Новартис Аг Применение кальцитонина при остеоартрите
BRPI0414175A (pt) * 2003-09-19 2006-10-31 Pfizer Health Ab método melhorado de tratamento de distúrbios do crescimento
US8030271B2 (en) * 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
NZ566397A (en) * 2005-09-19 2010-04-30 Emisphere Tech Inc Crystalline forms of the di-sodium salt of 5-CNAC

Also Published As

Publication number Publication date
WO2008027854A3 (en) 2008-07-03
CN103356997A (zh) 2013-10-23
US8323688B2 (en) 2012-12-04
RU2493868C2 (ru) 2013-09-27
WO2008027854A2 (en) 2008-03-06
BRPI0716261A2 (pt) 2013-08-06
EP2059260B1 (en) 2013-06-19
JP2010502639A (ja) 2010-01-28
PT2059260E (pt) 2013-09-03
AU2007289344A1 (en) 2008-03-06
KR20090045416A (ko) 2009-05-07
KR101524880B1 (ko) 2015-06-01
ES2426485T3 (es) 2013-10-23
US20100247608A1 (en) 2010-09-30
CA2661521C (en) 2016-04-12
AU2007289344B2 (en) 2011-04-14
CN101557827A (zh) 2009-10-14
CA2661521A1 (en) 2008-03-06
EP2059260A2 (en) 2009-05-20
PL2059260T3 (pl) 2014-03-31
RU2009111391A (ru) 2010-10-10
JP5042312B2 (ja) 2012-10-03

Similar Documents

Publication Publication Date Title
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EP2248519A3 (en) Non-mucoadhesive film dosage forms
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MY143795A (en) Tetrahydropyridoindole derivatives
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
NZ612063A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
MX2009011784A (es) Composicion para el suminitro transmucosal de polipeptidos.
DE602008006700D1 (es)
MX2011000319A (es) Uso de rifalazil para tratar trastornos colonicos.
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.
NZ602032A (en) Oral b12 therapy
MX2010013484A (es) Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.
MX2008011321A (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual.
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
PT2252263E (pt) Forma galénica para a administração de triptanos por via transmucosa bucal

Legal Events

Date Code Title Description
FG Grant or registration